Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Vaxart Inc Stock Research

VXRT

0.74USD+0.03(+4.23%)Market Closed
Watchlist

Market Summary

USD0.74+0.03
Market Closed
4.23%

VXRT Stock Price

VXRT RSI Chart

VXRT Valuation

Market Cap

112.7M

Price/Earnings (Trailing)

-1.12

Price/Sales (Trailing)

54.83

EV/EBITDA

-0.75

Price/Free Cashflow

-1.21

VXRT Price/Sales (Trailing)

VXRT Profitability

EBT Margin

-15454.95%

Return on Equity

-120.1%

Return on Assets

-83.02%

Free Cashflow Yield

-82.82%

VXRT Fundamentals

VXRT Revenue

Revenue (TTM)

2.1M

Revenue Y/Y

3.1K%

Revenue Q/Q

101.19%

VXRT Earnings

Earnings (TTM)

-100.9M

Earnings Y/Y

23.38%

Earnings Q/Q

10.3%

Price Action

52 Week Range

0.562.37
(Low)(High)

Last 7 days

-2.4%

Last 30 days

-6.1%

Last 90 days

-23.3%

Trailing 12 Months

-67.9%

VXRT Financial Health

Current Ratio

4.84

VXRT Investor Care

Shares Dilution (1Y)

20.21%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for VXRT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-06-26
Watson W. Mark
acquired
-
-
7,375
-
2023-06-26
Yedid Robert A.
acquired
-
-
7,375
-
2023-06-26
Wheadon David E.
acquired
-
-
7,375
-
2023-06-26
HERON ELAINE J
acquired
-
-
6,922
-
2023-06-26
Finney Michael J.
acquired
-
-
7,375
-
2023-06-12
Lee Phillip E
acquired
-
-
22,500
chief financial officer
2023-03-17
Floroiu Cezar Andrei
acquired
-
-
367,735
president, chief exec officer
2023-03-17
Cummings James F.
acquired
-
-
194,350
chief medical officer
2023-03-17
Lee Phillip E
acquired
-
-
101,652
chief financial officer
2023-03-17
Lee Phillip E
acquired
-
-
191,652
chief financial officer

1–10 of 50

Which funds bought or sold VXRT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-23
CTC Alternative Strategies, Ltd.
new
-
8,249
8,249
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
sold off
-100
-36,175
-
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-1.19
229
10,867
-%
2023-08-16
Nuveen Asset Management, LLC
sold off
-100
-1,680,000
-
-%
2023-08-15
HARBOUR INVESTMENTS, INC.
unchanged
-
-40.00
1,102
-%
2023-08-15
GOLDMAN SACHS GROUP INC
added
162
161,454
266,940
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
sold off
-100
-144,605
-
-%
2023-08-15
Belpointe Asset Management LLC
sold off
-100
-1,864
-
-%
2023-08-15
Rokos Capital Management LLP
new
-
365,250
365,250
-%
2023-08-15
IHT Wealth Management, LLC
reduced
-1.57
-9,969
187,696
0.01%

1–10 of 47

Latest Funds Activity

Are funds buying VXRT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VXRT
No. of Funds

Schedule 13G FIlings of Vaxart

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 07, 2023
blackrock inc.
1.3%
1,928,709
SC 13G/A
Feb 09, 2023
vanguard group inc
5.35%
7,019,507
SC 13G
Feb 01, 2023
blackrock inc.
6.7%
8,858,225
SC 13G/A
Jan 10, 2023
state street corp
1.83%
2,398,264
SC 13G/A
Mar 10, 2022
state street corp
10.39%
13,072,021
SC 13G/A
Feb 11, 2022
state street corp
8.91%
11,187,642
SC 13G/A
Feb 07, 2022
blackrock inc.
6.7%
8,452,420
SC 13G
Feb 11, 2021
state street corp
8.63%
9,444,967
SC 13G
Jun 09, 2020
armistice capital, llc
19.99%
16,785,583
SC 13D/A
May 27, 2020
armistice capital, llc
11.3%
8,400,000
SC 13D/A

Recent SEC filings of Vaxart

View All Filings
Date Filed Form Type Document
Sep 06, 2023
8-K
Current Report
Aug 03, 2023
8-K
Current Report
Aug 03, 2023
10-Q
Quarterly Report
Aug 01, 2023
4
Insider Trading
Aug 01, 2023
4
Insider Trading
Aug 01, 2023
4
Insider Trading
Aug 01, 2023
4
Insider Trading
Aug 01, 2023
4
Insider Trading
Jul 26, 2023
8-K
Current Report
Jul 10, 2023
8-K
Current Report

Peers (Alternatives to Vaxart)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
145.2B
26.6B
4.13% 21.09%
18.2
5.46
0.75% 21.34%
94.5B
27.4B
-0.16% 19.51%
17.24
3.45
-0.48% 32.56%
39.4B
10.7B
-6.80% -20.18%
32.68
3.7
-53.67% -91.41%
37.7B
10.0B
-1.71% 27.59%
14.15
3.78
-6.23% 29.40%
MID-CAP
11.2B
1.7B
5.59% 6.81%
63.29
6.67
29.01% 1345.90%
4.5B
-
-3.04% 140.92%
-7.66
48.33
54.84% -12.96%
3.1B
-
-4.51% -22.98%
-23.78
37.44
122.90% 54.78%
2.0B
80.2M
6.46% -52.82%
-6.01
24.54
42.17% -39.82%
SMALL-CAP
1.5B
121.2M
4.38% -25.42%
-5.13
12.17
-70.36% -531.73%
980.2M
15.3M
-15.63% 3.04%
-5.4
64.02
1090.59% -36.57%
664.9M
1.6B
-12.64% -74.33%
-1.13
0.42
23.74% 60.24%
221.7M
-
-17.58% -90.72%
-1.05
1.62
116.83% 16.61%
146.7M
-
-8.84% -84.12%
-0.74
0.61
113.96% -15.19%
112.7M
2.1M
-6.14% -67.90%
-1.12
54.83
487.70% -8.66%
4.1M
-
-12.28% -96.10%
-0.05
3.21
- -129.46%

Vaxart News

Nasdaq
3 Biotech Blockbusters to Turn $5000 Into $50000.
Nasdaq,
8 days ago
Simply Wall St

Returns for VXRT

Cumulative Returns on VXRT

-36.7%


7-Year Cumulative Returns

-25.3%


5-Year Cumulative Returns

-55.1%


3-Year Cumulative Returns

Risks for VXRT

What is the probability of a big loss on VXRT?

100%


Probability that Vaxart stock will be more than 20% underwater in next one year

100%


Probability that Vaxart stock will be more than 30% underwater in next one year.

100%


Probability that Vaxart stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VXRT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Vaxart was unfortunately bought at previous high price.

Drawdowns

Financials for Vaxart

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue90.1%2,055,0001,081,000107,000228,333349,667471,000892,0001,174,0001,239,0001,650,0004,046,0007,606,0007,795,0007,848,6007,902,2007,955,8008,009,4008,063,0004,159,0003,152,0003,786,000
Operating Expenses-4.2%111,244,000116,080,000114,694,000107,823,00095,848,00082,488,00073,644,00063,072,00053,475,00046,637,00034,216,00030,041,00027,355,00023,388,00025,647,00022,058,00023,051,00026,352,00025,915,00025,562,00022,272,000
  S&GA Expenses-12.7%25,630,00029,353,00029,386,00028,693,00026,775,00022,604,00021,890,00021,262,00020,410,00019,156,00015,202,00011,407,0008,672,0006,151,0006,187,0006,082,0006,301,0006,697,0006,681,0008,555,0007,505,000
  R&D Expenses-1.3%81,360,00082,473,00081,054,00076,125,00066,068,00056,879,00048,749,00041,810,00034,017,00028,394,00019,863,00014,563,00013,660,00012,253,00014,540,00015,723,00016,391,00017,696,00017,275,00015,301,00013,167,000
EBITDA100.0%--100,985,000-101,886,000-99,422,000-88,233,000-75,132,000-66,155,000---43,681,000-29,272,000-21,752,000-18,734,000-14,926,000-14,244,000-12,679,000-13,768,000-17,046,000---
EBITDA Margin100.0%--144-952-625-245-159-74.16---26.47-7.23-2.86-2.40-1.90-1.80-1.59-1.72-2.11---
Interest Expenses---------------315,000407,000452,000491,000821,0001,471,0002,110,000
Earnings Before Taxes6.4%-100,837,000-107,721,000-107,691,000-104,535,000-92,804,000-79,475,000-70,363,000-63,445,000-53,942,000-46,807,000-31,982,000-24,367,000-21,537,000-18,210,000-18,155,000-16,764,000-18,083,000-21,329,000-17,898,000-16,376,000-12,001,000
EBT Margin100.0%--154-1,006-657-258-168-78.88-54.04-43.54-28.37-7.90-3.20-2.76-2.32-2.30-2.11-----
Net Income6.4%-100,917,000-107,797,000-107,758,000-104,604,000-92,878,000-79,564,000-70,470,000-63,567,000-54,069,000-46,930,000-32,220,000-24,768,000-21,943,000-18,603,000-18,645,000-17,138,000-18,426,000-21,660,000-18,007,000-14,180,000-9,805,000
Net Income Margin100.0%--154-1,007-657-258-168-79.00-54.15-43.64-28.44-7.96-3.26-2.82-2.37-2.36-2.15-----
Free Cashflow100.0%--103,620,000-104,380,000-88,156,000-87,104,000-74,241,000-64,989,000-59,828,000-53,800,000-38,968,000-24,973,000-17,109,000-12,001,000-11,947,000-13,940,000-16,033,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-5.5%12313015417518120022124122920615315564.0053.0037.0043.0037.0036.0035.0041.0048.00
  Current Assets-6.0%71.0076.0099.0012013815416919218917512913646.0034.0018.0021.0017.0015.0015.0019.0026.00
    Cash Equivalents-10.6%43.0048.0046.0051.0091.0012314416716515712713344.0030.0014.0020.0016.008.0012.0018.0024.00
  Net PPE-3.2%14.0014.0016.0012.009.008.007.005.004.002.001.001.000.000.000.001.002.002.001.001.001.00
  Goodwill0%5.005.005.005.005.005.005.00--------------
Liabilities-6.3%38.0040.0043.0053.0038.0034.0034.0036.0029.0030.0029.0023.0024.0021.0024.0024.0021.0024.0024.0025.0025.00
  Current Liabilities-11.5%14.0016.0018.0022.0016.0011.0011.0013.0013.0012.0012.0010.0011.007.009.009.007.009.007.008.009.00
Shareholder's Equity-5.2%85.0090.0011112214316618820520017612313240.0031.0013.0019.0016.0013.0011.0016.0022.00
  Retained Earnings-6.4%-374-352-327-303-273-244-219-198-181-164-148-135-126-117-116-110-104-99.35-97.99-93.09-86.54
  Additional Paid-In Capital4.0%460442438426417411407404381341272267167142130125119111109108108
Shares Outstanding12.1%15213613412812612612612412111511010868.0061.0022.0013.0011.007.006.006.005.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations9.0%-85.70-94.13-94.78-81.44-81.09-68.35-59.83-54.78-49.77-37.13-23.75-16.78-11.85-11.64-13.09-15.00-16.03-8.61-14.55-13.55-12.69
  Share Based Compensation3.9%14.0013.0014.0013.0012.0011.009.006.005.006.004.004.003.001.001.001.001.001.001.001.001.00
Cashflow From Investing554.9%9.001.00-20.41-44.39-17.73-24.81-49.10-41.82-37.72-21.78-1.22-0.33-0.15-0.30-0.85-1.03-1.08-1.1226.0041.0047.00
Cashflow From Financing62.0%29.0018.0017.009.0025.0059.0012613020818613813140.0033.0016.0018.009.001.00-1.73-1.61-1.48

VXRT Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue from Contract with Customer, Including Assessed Tax$ 1,358$ 0$ 2,033$ 85
Operating expenses:    
Research and development18,81319,92638,43538,129
General and administrative5,5989,32112,22315,979
Total operating expenses24,41129,24750,65854,108
Operating loss(23,053)(29,247)(48,625)(54,023)
Other income (expense):    
Interest income7111571,353192
Non-cash interest expense related to sale of future royalties(188)(323)(366)(663)
Foreign exchange loss, net(1)(2)(4)(2)
Loss before income taxes(22,531)(29,415)(47,642)(54,496)
Provision for income taxes19154835
Net loss$ (22,550)$ (29,430)$ (47,690)$ (54,531)
Net loss per share - basic and diluted (in dollars per share)$ (0.16)$ (0.23)$ (0.35)$ (0.43)
Shares used to compute net loss per share - basic and diluted (in shares)139,594,238126,428,298137,403,416126,111,777
Comprehensive loss:    
Net loss$ (22,550)$ (29,430)$ (47,690)$ (54,531)
Unrealized gain (loss) on available-for-sale investments, net of tax46(100)275(335)
Comprehensive loss(22,504)(29,530)(47,415)(54,866)
Non Cash Royalty Revenue [Member]    
Revenue from Contract with Customer, Including Assessed Tax30030885
Grant [Member]    
Revenue from Contract with Customer, Including Assessed Tax$ 1,328$ 0$ 1,725$ 0

VXRT Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash, cash equivalents and restricted cash$ 43,277$ 46,013
Short-term investments24,62849,704
Accounts receivable2920
Prepaid expenses and other current assets3,3273,714
Total current assets71,26199,451
Property and equipment, net13,91815,585
Right-of-use assets, net26,80425,715
Intangible assets, net4,6545,020
Goodwill4,5084,508
Other long-term assets1,5083,568
Total assets122,653153,847
Current liabilities:  
Accounts payable4,1995,514
Deferred grant revenue2752,000
Other accrued current liabilities6,0508,084
Current portion of operating lease liability2,4302,228
Current portion of liability related to sale of future royalties92995
Total current liabilities13,88317,921
Operating lease liability, net of current portion18,56619,477
Liability related to sale of future royalties, net of current portion4,8695,621
Other long-term liabilities262231
Total liabilities37,58043,250
Commitments and contingencies (Note 8)
Stockholders’ equity:  
Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of June 30, 2023 and December 31, 202200
Common stock: $0.0001 par value; 250,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 152,016,238 shares issued and 151,982,992 shares outstanding as of June 30, 2023 and 134,199,429 shares issued and outstanding as of December 31, 2022.1513
Additional paid-in capital459,912437,992
Treasury stock at cost, 33,246 shares and none as of June 30, 2023 and December 31, 2022, respectively(31)0
Accumulated deficit(374,799)(327,109)
Accumulated other comprehensive loss(24)(299)
Total stockholders’ equity85,073110,597
Total liabilities and stockholders’ equity$ 122,653$ 153,847
Andrei Floroiu
110
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.